An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a clinical phase 0 imaging study in cardiac fibrosis patients and the preclinical development of a targeted therapeutic, with BiOrion’s PDGF beta receptor binding bicyclic peptide conjugates.
EFRO TENDER VALORISATIE 2017 is a program of the European Regional Development Fund from the European Commission, co-funded from the national budgets of Participating States, Partner Countries and by the European Union through Horizon 2020.
Herman Steen, CEO of BiOrion, said “This European Union EFRO grant will further enable BiOrion to progress its clinical development of its novel myofibroblast targeting platform. It is an ongoing recognition and support for our PDGF-beta-receptor binding bicyclic peptide drug-conjugates technology.”
About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis, hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-beta-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.
Herman Steen, PhD
CEO BiOrion Technologies BV